AVTE - Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday? | Benzinga
Monday, Aerovate Therapeutics Inc (NASDAQ:AVTE) released topline results from the Phase 2b portion of the IMPAHCT Phase 2b/3 trial of AV-101, a dry powder inhaled formulation of imatinib, for pulmonary arterial hypertension (PAH).
Aerovate Therapeutics shares are trading lower on a session volume of 4.8 million versus an average volume of 213.43K, as per data from Benzinga Pro.
Developed specifically for pulmonary arterial hypertension, AV-101 targets cellular hyperproliferation and resistance to apoptosis, driven by improper signaling in cells of the distal pulmonary ...